Clinical trials
Psychosis Associated With Alzheimer's Disease clinical trials
Below are recruiting psychosis associated with alzheimer's disease clinical trials, each written for real people, not researchers. We’re tracking 22 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05511363RecruitingPhase 3
Study of a new medicine for psychosis in Alzheimer's disease
This trial tests a new drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. If you or a loved one has Alzheimer's and experiences these symptoms, this study might offer a new treatment option.
Homewood, AlabamaAges 55–90 - NCT07459660Enrolling by invitationPhase 2
Long-term study of ML-007C-MA for Alzheimer's psychosis
This trial tests a long-term treatment (ML-007C-MA) for people with Alzheimer's disease who have psychosis. It is for those who already completed an earlier study with the same drug and may benefit from continuing it. The goal is to see if ongoing treatment is helpful and safe.
Anaheim, CaliforniaAges 55–91 - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Homewood, AlabamaAges 55–90 - NCT06126224RecruitingPhase 3
Testing KarXT for Alzheimer's-related psychosis
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
Chandler, ArizonaAges 55–90 - NCT06540833RecruitingPhase 2
Study of ITI-1284 for psychosis in Alzheimer's disease
This trial tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis (hallucinations or delusions) in people with Alzheimer's disease. It may be an option for patients who have both Alzheimer's and related psychotic symptoms.
Anaheim, CaliforniaAges 55 years+ - NCT06887192RecruitingPhase 2
Testing ML-007C-MA for Alzheimer's Psychosis
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
Phoenix, ArizonaAges 55–90 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95 - NCT05847192Recruiting
Testing brain-signal networks in Alzheimer’s with hallucinations
This study looks at “tau” (a brain protein) and brain-signal patterns in people with Alzheimer’s disease who have psychotic symptoms like hallucinations or delusions. It may help researchers understand what’s happening in the brain and how to better target these symptoms.
Manhasset, New YorkAges 65–85 - NCT06597942RecruitingPhase 1/Phase 2
Deep TMS for Alzheimer's disease
This trial tests a non-invasive brain stimulation technique called deep repetitive TMS on a brain region linked to memory. It aims to see if this treatment can improve symptoms in people with mild-to-moderate Alzheimer's disease.
Los Angeles, CaliforniaAges 60–100 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Chandler, ArizonaAges 55–90 - NCT06947941RecruitingPhase 3
Testing karxt for psychosis in alzheimer's disease
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
Gilbert, ArizonaAges 55–90 - NCT06860828Enrolling by invitation
Football players and brain health study: DIAGNOSE CTE
This study looks at brain changes in former college and professional football players, people with memory problems, and healthy controls. It aims to learn more about chronic traumatic encephalopathy (CTE) and Alzheimer's disease.
Phoenix, ArizonaAges 50 years+ - NCT06254469RecruitingPhase 3
PET scan study for memory decline with head injury or Alzheimer's risk
This trial uses a special PET scan tracer to see if it can predict who will get worse over time. It is for people with mild memory or thinking problems that may be linked to past head injuries or early Alzheimer's disease.
Evanston, IllinoisAges 45 years+ - NCT06837272Recruiting
Gut health and brain health in Alzheimer's disease
This study looks at how the bacteria in your gut might be connected to memory and thinking problems in Alzheimer's disease. It may help us understand if changes in the gut can affect brain health.
Jining, ShandongAges 60–80 - NCT07094438RecruitingPhase 1
Brain stimulation and neck surgery for severe Alzheimer's
This early-stage trial tests combining deep brain stimulation (a device that sends electrical pulses to the brain) with a neck surgery that aims to improve brain fluid drainage. It's for people with severe Alzheimer's who can still walk and do not have other major health issues.
BeijingAges 40–80 - NCT05824728RecruitingPhase 2
Levetiracetam for Parkinson’s psychosis with study partner support
This Phase 2 study tests whether AGB101 (levetiracetam) can reduce hallucinations, delusions, or related symptoms in people with Parkinson’s disease psychosis, while checking safety. You and a study partner will help with dosing and regular check-ins, including MRI scans.
Baltimore, MarylandAges 40–85 - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Miami, FloridaAges 50 years+ - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT06976203RecruitingPhase 3
Testing karxt for thinking problems in alzheimer's
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Fullerton, CaliforniaAges 60–85 - NCT06793735Recruiting
Virtual reality app for memory and thinking problems
This trial tests a virtual reality app you can use at home to help with early memory or thinking problems. It may be an option if you have mild cognitive impairment or notice your thinking is slowing down.
Messina, ItalyAges 40–80 - NCT05468905Recruiting
Study of aging and early thinking changes over time
This study follows adults 40+ to better understand and track changes in memory and thinking as people age. It groups people with normal thinking, subjective complaints, mild cognitive impairment, early Alzheimer’s, and vascular (blood vessel) related brain changes to find what predicts progression.
Hangzhou, ZhejiangAges 40–99 - NCT05568498RecruitingPhase 2
Probiotic trial for depression in Parkinson’s disease
This Phase 2 study tests whether taking probiotics can improve depression and mood symptoms in people with Parkinson’s disease. It’s meant for those with mild to moderate depression and stable Parkinson’s and mood treatments.
Vancouver, British ColumbiaAges 40–80
Hear when a new Psychosis Associated With Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Psychosis Associated With Alzheimer's Disease trials by city
Studies with a site in or near these metro areas.
Psychosis Associated With Alzheimer's Disease trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for psychosis associated with alzheimer's disease?
- Yes. Clin2 currently lists 22 recruiting psychosis associated with alzheimer's disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psychosis associated with alzheimer's disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psychosis associated with alzheimer's disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.